Vol. 4 No. 3 (2024)
Reimbursement Reviews

Andexanet Alfa (Ondexxya)

decorative image of the issue cover

Published March 8, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses andexanet alfa (Ondexxya), 200 mg, powder for solution for infusion, IV infusion.
  • Indication: For adult patients treated with FXa inhibitors (rivaroxaban or apixaban) when rapid reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.